Skip to main content
Premium Trial:

Request an Annual Quote

FDA Reissues Color Coronavirus Test EUA for Sample Collection Changes

NEW YORK — The US Food and Drug Administration on Monday reissued an Emergency Use Authorization for Color's loop-mediated isothermal amplification-based SARS-CoV-2 test to reflect changes in the use of self-collected samples.

In May, the Color SARS-CoV-2 LAMP Diagnostic Assay received EUA for the detection of the SARS-CoV-2 N, E, and ORF1a genes in nasopharyngeal swabs, oropharyngeal swabs, anterior nares swabs, mid-turbinate nasal swabs, nasopharyngeal wash/aspirate or nasal aspirates, and bronchoalveolar lavage specimens.

The EUA was later updated to reflect the test's removal of ORF1a as a target and include the use of Color's COVID-19 Test Unmonitored Collection Kit for the self-collection of nasal swab specimens at home or in a healthcare setting.

This week's reissuance removes the Color COVID-19 Unmonitored Collection Kit from the EUA due to the kit's recent authorization on its own, as well as updates the SARS-CoV-2 test's intended use to include dry nasal swabs self-collected at home or in a healthcare setting using the Color COVID-19 Self-Swab Collection Kit when deemed appropriate by a healthcare provider. 

Use of the test remains limited to Burlingame, California-based Color.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.